Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc. has announced that their lead compound, RuvidarTM, shows promise in inactivating various viruses, including the potential to be used as a broad-spectrum viral vaccine. Research indicates RuvidarTM is highly potent, even at low concentrations, and maintains the integrity of the coronavirus spike protein, suggesting vaccine applications. The company aims to further develop RuvidarTM as an antiviral platform and a topical therapeutic for herpes virus lesions.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
